EP1844331A4 - Dispositif d'immunodosage non continu et méthode d'immunodosage doté dudit dispositif - Google Patents

Dispositif d'immunodosage non continu et méthode d'immunodosage doté dudit dispositif

Info

Publication number
EP1844331A4
EP1844331A4 EP05726908A EP05726908A EP1844331A4 EP 1844331 A4 EP1844331 A4 EP 1844331A4 EP 05726908 A EP05726908 A EP 05726908A EP 05726908 A EP05726908 A EP 05726908A EP 1844331 A4 EP1844331 A4 EP 1844331A4
Authority
EP
European Patent Office
Prior art keywords
pad
immunoassay device
sample
immunoassay
connecting member
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05726908A
Other languages
German (de)
English (en)
Other versions
EP1844331A1 (fr
Inventor
Young-Shik Cho
Hyo-Keun Lee
Byung-Ki Cho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Standard Diagnostics Inc
Original Assignee
Standard Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Standard Diagnostics Inc filed Critical Standard Diagnostics Inc
Publication of EP1844331A1 publication Critical patent/EP1844331A1/fr
Publication of EP1844331A4 publication Critical patent/EP1844331A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K93/00Floats for angling, with or without signalling devices
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5023Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54386Analytical elements
    • G01N33/54387Immunochromatographic test strips
    • G01N33/54388Immunochromatographic test strips based on lateral flow
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K97/00Accessories for angling
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06Fluid handling related problems
    • B01L2200/0621Control of the sequence of chambers filled or emptied
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/08Geometry, shape and general structure
    • B01L2300/0809Geometry, shape and general structure rectangular shaped
    • B01L2300/0825Test strips
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/08Geometry, shape and general structure
    • B01L2300/0861Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/087Multiple sequential chambers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/08Geometry, shape and general structure
    • B01L2300/0887Laminated structure
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/06Valves, specific forms thereof
    • B01L2400/0633Valves, specific forms thereof with moving parts

Definitions

  • This invention relates to a non-continuous immunoassay device. More particularly, this invention relates to a non-continuous immunoassay device which includes two or more separated pads for immunoassay analysis, and is capable of controlling the migration speed of a mobile phase between the separated pads, and an immunoassay method using the same.
  • the immunochromatographic assay known as a rapid testing method has been developed for a simple, qualitative and quantitative analysis of a small amount of analyte.
  • the assay utilizes antigen-antibody reaction for analysis, and is applied in various fields such as a medical field for diagnosing diseases, agriculture, livestock raising, foods, military, environment and so on.
  • the immunochromatographic assay is carried out with an assay strip, or with an assay device which comprises a plastic case and the assay strip installed in the case.
  • Fig. 1 is a cross- sectional view of the conventional assay strip for immunochromatographic assay. As shown in the Fig.
  • the conventional assay strip 10 includes a sample pad 12 for receiving a liquid sample, a conjugate pad 14 containing a conjugate, a porous membrane pad 16 immobilized with a binder( antibody or antigen) 16a which specifically combines with an analyte in the sample and/or the conjugate, and an absorbent pad 18 for finally receiving the liquid sample.
  • the conjugate is produced by conjugating a label which generates a signal detectable by naked eyes or a sensor to a ligand such as an antigen or an antibody.
  • These pads are consecutively arranged on a plastic backing 20, and the connecting ends of the neighboring pads are overlapped by a predetermined distance.
  • a sample receiving hole for introducing a sample to the sample pad 12 and a result observation window for observing the test result are formed on the upper portion of the case.
  • a liquid sample is injected into the sample pad 12.
  • the injected liquid sample flows along the conjugate pad 14 and the porous membrane pad 16 by a capillary action, and is finally absorbed by the absorbent pad 18.
  • the conjugate contained in the conjugate pad 14 also migrates along with the liquid sample. If a target analyte exists in the sample, the conjugate is bound to the binder 16a which is immobilized on the porous membrane pad 16 via the target analyte (sandwich reaction), or the conjugate and the target analyte are competitively bound to the binder 16a (competition reaction).
  • the existence of the analyte can be determined by detecting the conjugate bound to the binder 16a with naked eyes or a sensor.
  • the pore size of the porous membrane pad 16 should be modified.
  • the flow rate of the liquid sample and the reaction rate of antigen-antibody reaction cannot be controlled effectively with the conventional assay strip 10. Namely, the reaction of the liquid sample and a diluent for diluting the liquid sample, and/or the antigenantibody reaction between the binder 16a, the liquid sample and the conjugate cannot be carried out for enough time interval, which deteriorates the sensitivity and specificity of the immunochromatographic assay.
  • the conventional assay strip 10 has further disadvantage in that the shape of the assay strip 10 or the shape of the assay device including the strip 10 is limited to the rod shape.
  • the present invention provides an immunoassay device, which includes the first pad including a sample pad for receiving a liquid sample; the second pad which is spatially separated from the first pad by a predetermined distance, and to which the liquid sample is migrated; an upper case for covering the upper parts of the first pad and the second pad; a lower case for covering the lower parts of the first pad and the second pad; and a connecting member which is formed on at least one of the upper case and the lower case, and located between the first pad and the second pad to form a passage for moving the liquid sample.
  • the present invention also provides an immunoassay device, which includes a strip shaped plastic backing; two or more pads for immunoassay that are formed on the plastic backing and spatially separated from each other by a predetermined distance; an upper case for covering the upper parts of the two or more pads; a lower case for covering a lower part of the plastic backing; and at least one connecting member which is formed on at least one of the upper case and the lower case, and located between the pads to form a passage for moving the liquid sample.
  • the present invention further provides a method for immunoassay.
  • the method includes the steps of: applying a liquid sample into a sample pad; migrating the liquid sample through a capillary passage which is formed between an upper case and a lower case for covering the sample pad, and formed by a protrusion extending from at least one of the upper case and the lower case; and analyzing the liquid sample which is moved through the capillary passage by using an antigen- antibody reaction.
  • FIG. 1 is a cross-sectional view of a conventional assay strip
  • FIG. 2 is an exploded perspective view of a non-continuous immunoassay device according to the first embodiment of the present invention
  • FIG. 3 is a side cross-sectional view of a non-continuous immunoassay device according to the first embodiment of the present invention
  • FIG. 4 shows a front view(A), a bottom view(B) and a side view(C) of a connecting member of the non-continuous immunoassay device according to the first embodiment of the present invention
  • Fig. 5 is a side cross-sectional view of a non-continuous immunoassay device according to the second embodiment of the present invention
  • FIG. 6 is a side cross-sectional view of a non-continuous immunoassay device according to the third embodiment of the present invention.
  • Fig. 7 is a modified example of a non-continuous immunoassay device according to the third embodiment of the present invention.
  • FIG. 8 is an exploded perspective view of a non-continuous immunoassay device according to the fourth embodiment of the present invention.
  • FIG. 9 is a side cross-sectional view of a non-continuous immunoassay device according to the fourth embodiment of the present invention.
  • FIG. 10 shows a front view(A), a bottom view(B) and a side view(C) of a connecting member of the non-continuous immunoassay device according to the fourth embodiment of the present invention
  • FIG. 11 is a modified example of a non-continuous immunoassay device according to the fourth embodiment of the present invention.
  • Fig. 12 is a partially cut-away top view of a non-continuous immunoassay device according to the fifth embodiment of the present invention.
  • FIG. 13 is an exploded perspective view of a non-continuous immunoassay device according to the sixth embodiment of the present invention.
  • Figs. 2 and 3 are an exploded perspective view and a side cross-sectional view, respectively, of a non-continuous immunoassay device according to the first embodiment of the present invention.
  • the immunoassay device according to the first embodiment of the present invention includes the first pad 32 and the second pad 34 which are spatially separated from each other by a predetermined distance.
  • the upper and the lower parts of the first and second pad 32,34 are covered with an upper case 52 and a lower case 72, respectively.
  • the first and the second pad 32, 34 can be fixed on the lower case 72 by being inserted between a plurality of guides 74 formed on the lower case 72, or can be fixed in grooves (not shown) formed on the upper or lower case 52, 72.
  • a pad-supporting member 76 can be formed on the lower case 72 for supporting the first and the second pad 32, 34.
  • the pad-supporting member 76 can be made of a plate shaped shock-absorbing plastics.
  • a connecting member 60 is formed on the upper case 52 so that the connecting member 60 is located in the space 30 between the first pad 32 and the second pad 34 when the upper case 52 and the lower case 72 are assembled.
  • the connecting member 60 can be a protrusion which is separated from the lower case 72 or the optionally formed pad-supporting member 76 by a predetermined distance when the upper case 52 and the lower case 72 are assembled.
  • the liquid sample applied to the first pad 32 migrates to the second pad 34 through the gap between the connecting member 60 and the lower case 72 or between the connecting member 60 and the pad- supporting member 76 by a capillary action. Therefore, the connecting member 60 produces capillary passage (gap) for migrating the liquid sample in the space 30 between the first pad 32 and the second pad 34.
  • the connecting member 60 can be a liquid non-permeable protrusion extending from the upper case 52, and if necessary, can be formed on the lower case 72 or formed on both of the upper case 52 and the lower case 72.
  • examples of the first pad 32 and the second pad 34 include (i) a sample pad 12 for receiving a liquid sample that are expected to contain a target analyte and/or a diluent for diluting the liquid sample, (ii) a conjugate pad containing a conjugate, which is produced by conjugating a label (for example, gold particles, colored polystyrene micro particles, enzyme, fluorescent dye, conductive polymer, magnetic particles) which generates a signal detectable by naked eyes or a sensor to a ligand (for example, an antigen or an antibody) which can bind with the analyte, (iii) an optional auxiliary pad containing a material for facilitating the antigen- antibody reaction or for suppressing a nonspecific reaction when whole blood is used as the liquid sample, (iv) a porous membrane pad 16, on which at least one detection zone(test line) is formed by immobilizing a binder (antibody or antigen) which
  • the first pad 32 includes the sample pad 12 for receiving the liquid sample
  • the second pad 34 includes one or more pads to which the liquid sample migrates.
  • the first pad 32 is the sample pad 12
  • the second pad 34 includes the porous membrane pad 16 and the absorbent pad 18 which overlaps at their connecting ends.
  • the first pad 32 may include two or more pads, which either overlaps at their connecting ends or are separated from each other, and the examples of the two or more pads include (i) the sample pad 12 and a conjugate pad, (ii) the sample pad 12 for whole blood, an auxiliary pad, and a conjugate pad, and so on.
  • the second pad 34 can include other necessary immunoassay pads.
  • the auxiliary pad can contain a material for facilitating an antigen- antibody reaction or for suppressing a nonspecific reaction when whole blood is used as the sample.
  • the auxiliary pad can contain a reagent which is necessary for analysis but hemolyzes a RBC(Red Blood Cell) when mixed with whole blood sample.
  • the auxiliary pad can be installed between the sample pad 12 and the conjugate pad so that the material contained in the auxiliary pad can be mixed with the liquid sample from which RBC is filtered by the sample pad 12.
  • the porous membrane pad 16 can be made of a porous material, such as nitrocellulose, glass fiber, polyethersulfone(PES), cellulose, nylon, and so on, and preferably can be made of nitrocellulose having the pore size of about 5D to 15D.
  • the first pad 32 and the second pad 34 can be formed on the upper portions of two separate plastic backings 20a, 20b, respectively. By using the plastic backings 20a, 20b, the first pad 32 and the second pad 34 can be produced more conveniently and can be easily mounted on the lower case 72.
  • the plastic backings 20a, 20b can be made of a material such as polypropylene film, polyester film, polycarbonate film, acrylic film, or so on, and can be preferably made of polypropylene film.
  • Fig. 4 shows a front view(A), a bottom view(B) and a side view(C) of the connecting member 60 which is formed on the upper case 52 and/or the lower case 72.
  • the connecting member 60 can be a protrusion 64 having shoulders 62a, 62b which are formed to the directions of the first pad 32 and the second pad 34.
  • the shoulders 62a, 62b compress and fix the end of the first pad 32 and the end of the second pad 34, and the protrusion 64 forms the capillary passage between the first pad 32 and the second pad 34. Therefore, it is preferable that the protrusion 64 is firmly inserted into the space 30 between the first pad 32 and the second pad 34.
  • a plurality of micro-protrusions 66 is formed on the shoulder 62a, 64b for firm fixing of the first and the second pad 32, 34. It is also preferable that a plurality of micro-protrusions 68 is formed on the protrusion 64 for forming a regular capillary passage by maintaining the gap distance between the protrusion 64 and the pad-supporting member 76. By forming the micro-protrusion 68 on the protrusion 64, the capillary passage can be formed around the micro-protrusion 68 even though the micro-protrusion 68 contacts with the pad-supporting member 76.
  • the micro- protrusion 66, 68 may be a straight line shaped protrusion formed along the direction of the migration of the liquid sample as shown in Fig. 4, but not limited thereto, and can be semi- spherical shaped protrusion, hexahedron shaped protrusion, and so on.
  • the gap distance between the connecting member 60, specifically, the protrusion 64 and the lower case 72 or the pad-supporting member 76 can be adjusted by changing the heights of the protrusion 64 and micro- protrusion 68. By adjusting the gap distance, the migration speed of the mobile phase such as liquid sample passing through the connecting member 60 can be controlled. Therefore, the antigen-antibody reaction rate can also be controlled.
  • the distance between the first pad 32 and the second pad 34 and the gap distance of capillary passage formed between the upper case 52 and the lower case 72 can be properly determined according to the kind of antigen- antibody reaction and/or the kind of sample.
  • the distance between the first pad 32 and the second pad 34 is from 0.5 to 5mm, preferably from 1 to 3mm, and more preferably about 2mm
  • the gap distance of capillary passage is from 0.005 to lmm, preferably from 0.01 to 0.5mm, and more preferably from 0.01 to 0.2mm.
  • the distances are more than the above defined ranges or less than the above defined ranges, the migration of the liquid sample may not be properly performed.
  • the connecting member 60 can be treated with hydrophobic or hydrophilic materials to control the antigen-antibody reaction rate. Generally, it is difficult for aqueous solution to pass a hydrophobic region. When a compound in the aqueous solution is binded to the hydrophobic region, the hydrophobic region is changed to a hydrophilic region, and then aqueous solution can pass more easily the hydrophilic region. Therefore, if the connecting member 60 is treated with hydrophobic or hydrophilic materials, the migration speed of a mobile phase which migrates from the first pad 32 to the second pad 34 can be controlled. For example, when the connecting member 60 is treated to reduce the migration speed, the first pad 32 works as a reaction chamber for holding the reaction mixture for a predetermined time.
  • the methods of treating the connecting member 60 includes the method of coating the connecting member 60 with hydrophobic or hydrophilic latex particles or compounds, the method of adhering hydrophobic or hydrophilic group on the connecting member 60 by using a plasma, and so on.
  • hydrophobic latex particle include polymer such as polystyrene, polypropylene, polyethylene, polyester, and so on.
  • hydrophilic latex particle include polymer having hydrophilic group such as carboxyl, amine, and hydroxyl group on its surface.
  • the useful hydrophobic compound includes ink and a long chain fatty acid such as palmitic acid, stearic acid, or oleic acid
  • the useful hydrophilic compound includes hydrophilic polymer such as surfactant, glycerol, and polyvinyl alcohol.
  • a hydrophilic monomer such as acrylic monomer, methacrylic monomer, unsaturated amide, diene monomer, triene monomer or so on can be plasma graft polymerized on the surface of the connecting member 60, or oxygen or nitrogen can be treated with a hydrogen plasma on the connecting member 60.
  • a sample receiving hole 55 is formed on the upper case 52 at the position corresponding to the sample pad 12, and an observation window 56 is formed on the upper case 52 at the position corresponding to the detection zone of the porous membrane pad 16.
  • a diluent receiving hole 54 can be formed at the position corresponding to the end portion of the sample pad 12, and an air ventilation hole 58 can be formed at the position corresponding to the absorbent pad 18.
  • the air ventilation hole 58 is provided for air- ventilation at the absorbent pad 18, and prevents the liquid sample in the absorbent pad 18 from flowing backward to the observation window 56. Therefore, background clearance of the test result is induced, and the result of immunoassay can be observed more clearly.
  • the air ventilation hole 58 can be formed at the lateral position of the absorbent pad 18, or can be formed at both of upper and lateral positions of the absorbent pad 18. If necessary, a plurality of guides and protrusions can be formed on the upper case 52 and the lower case 72 for disposing, fixating, or compressing the immunoassay pads appropriately.
  • the upper case 52 and the lower case 72 can be assembled by typical connecting means such as connecting grooves and protrusions. Alternatively, the upper case 52 and the lower case 72 can be provided as an integrated form, namely, as a single body.
  • a liquid sample is applied to the first pad 32, i.e., sample pad 12 through the sample receiving hole 55 of the upper case 52.
  • the applied sample migrate through the capillary passage formed by the connecting member 60 to the second pad 34 consisting of the porous membrane pad 16 and the absorbent pad 18. Because the gap distance of the capillary passage is adjusted according to the analyte in the sample, the conjugate, and the antigen- antibody reaction, the antigen- antibody reaction(s) can be carried out for desired time interval at each pad. Therefore, the connecting member 60 works as a reaction barrier inducing a flow delay of the mobile phase, or works as an antigen- antibody reaction rate controller.
  • the liquid sample and/or the conjugate that migrate to the porous membrane pad 16 react with a binder immobilized on the porous membrane pad 16, and generate a signal detectable by naked eyes or a sensor.
  • FIG. 5 is a side cross-sectional view of a non-continuous immunoassay device according to the second embodiment of the present invention.
  • the immunoassay device of this embodiment has substantially same configuration with that of the first embodiment except that the first, the second and the third pads 32, 34, 36 are separated by predetermined distances, and consecutively formed on the two plastic backings 20a, 20b, and the first connecting member 60a is located at the space 30a between the first pad 32 and the second pad 34, and the second connecting member 60b is located at the space 30b between the second pad 34 and the third pad 36.
  • the first pad 32 is a sample pad 12
  • the second pad 34 is a conjugate pad 14 or an auxiliary pad
  • the third pad 36 includes a porous membrane pad 16 and an absorbent pad 18 which are overlapped at their connecting ends.
  • the first pad 32 and the second pad 34 are formed on the first plastic backing 20a
  • the third pad 36 is formed on the second plastic backing 20b.
  • three pads for example, a sample pad 12, an auxiliary pad, and a conjugate pad 14, which are separated by predetermined distances, can be formed on the first plastic backing 20a, and a porous membrane pad 16 can be formed on the second plastic backing 20b.
  • the four pads can be connected with total three connecting members.
  • the migration rate of the mobile phase passing each pad can be controlled individually, which increases the sensitivity of immunoassay more effectively.
  • only the damaged pad can be exchanged instead of discarding whole pads.
  • a detection zone containing a binder which can bind with the ligand of the conjugate is formed on the porous membrane pad 16, and the binder can be the same substance with the target analyte in the sample or the similar derivatives of the target analyte.
  • the signal intensity generated by the label of the conjugate is proportional or inversely proportional to the amount of the analyte in the sample.
  • the existence of the analyte can be determined qualitatively, such as, positive or negative.
  • the amount of the analyte can be determined quantitatively by comparing the detected signal intensity with a standard signal intensity or with a standard colorimetry table.
  • Fig. 6 is a side cross-sectional view of a non-continuous immunoassay device according to the third embodiment of the present invention
  • Fig. 7 is a modified example of the non-continuous immunoassay device according to the third embodiment.
  • the immunoassay device of the third embodiment has substantially same configuration with that of the first embodiment except that the immunoassay device includes the first pad 32 and the second pad 34 that are spatially isolated from each other by a predetermined distance, and are formed on single strip shaped plastic backing 20, and optionally a buffering groove 78 is formed on the lower case 72 or on the pad-supporting member 76 under the space 30 between the first pad 32 and the second pad 34 for regular migration of the liquid sample.
  • the width of the buffering groove 78 is larger than the distance between the first pad 32 and the second pad 34. Therefore, when the ends of the first pad 32 and the second pad 34 are compressed by the shoulder 62a, 62b of the connecting member 60, the compressed ends of the first pad 32 and the second pad 34 can be downwardly displaced due to the buffering groove 78, which facilitate the uniform migration of the liquid sample.
  • the first pad 32 can be a sample pad 12
  • the second pad 34 can be a porous membrane pad 16 and an absorbent pad 18 which are overlapped at their connecting ends.
  • a plurality of pads can be mounted on the single strip shaped plastic backing 20, and a plurality of pads is spatially isolated by at least two parts.
  • the four separated pads namely, the first pad 32, the second pad 33, the third pad 34, and the fourth pad 36 are mounted on the single strip shaped plastic backing 20, and four pads are connected by the three connecting members 60a, 60b, 60c.
  • the first pad 32, the second pad 33, the third pad 34, and the fourth pad 36 are a sample pad 12, an auxiliary pad 13, a conjugate pad 14, and an overlapped porous membrane pad 16 and absorbent pad 18, respectively.
  • the auxiliary pad 13 can be optionally formed as already described.
  • Fig. 8 is an exploded perspective view of a non-continuous immunoassay device according to the fourth embodiment of the present invention
  • Fig. 9 is a side cross- sectional view of the non-continuous immunoassay device.
  • the immunoassay device in accordance with the fourth embodiment includes the three separated pads, namely, the first pad 32, the second pad 33, and the third pad 34. Both the first pad 32 and the second pad 34 are formed on the first plastic backing 20a and the third pad 36 is formed on the second plastic backing 20b. Since the first pad 32, the second pad 34, and the third pad 36 are separated from each other, the shapes of the upper case 52 and the lower case 72 can be modified as occasion demands.
  • the portions of the upper case and the lower case which cover the second pad can be slanted with respect to the portions of the upper case and the lower case which cover the first pad by a predetermined angle.
  • the portions of the upper case 52 and the lower case 72 which cover the first pad 32 (a sample pad 12) and the second pad 34 (a conjugate pad 14 or an auxiliary pad) are formed to be parallel to the ground, and the portions of the upper case 52 and the lower case 72 which cover the third pad 36 (a porous membrane pad 16 and an absorbent pad 18) are formed to be slanted with respect to the ground by a predetermined angle, for example 30 to 50 degree with respect to the ground.
  • the bent configuration of the immunoassay device makes the user to easily observe the test result through the observation window 56.
  • the first connecting member 60a for connecting the first pad 32 and the second pad 34 has the same configuration with that of the first embodiment of the present invention.
  • Fig. 10 shows a front view(A), a bottom view(B) and a side view(C) of the second connecting member 60c for connecting the second pad 34 and the third pad 36 which is slanted by a predetermined angle.
  • the second connecting member 60c includes the first slanted protrusion 64a formed on the lower case 72 and the second slanted protrusion 64b formed on the upper case 52.
  • the slanted surface of the second slanted protrusion 64b corresponds to the slanted surface of the first slanted protrusion 64a and a gap is formed between the two surfaces.
  • a shoulder 62a can be formed at one or more side of the second slanted protrusion 64b for compressing the end of the second pad 34.
  • the slanted surface of the first slanted protrusion 64a and the slanted surface of the second slanted protrusion 64b are separated by a predetermined distance (a gap distance) to form a capillary passage therebetween.
  • first and the second slanted protrusion 64a, 64b are tightly located at the space between the second pad 34 and the third pad 36. It is also preferable that straight line shaped micro-protrusions 66 are formed on the shoulder 62a for tightly fixing the second pad 34, and straight line shaped micro-protrusions 68 are formed on the slanted surfaces of the first and second slanted protrusions 64a, 64b for forming uniform capillary passage. If necessary, two or more pads can be formed on the first plastic backing 20a. As shown in Fig.
  • three separated pads 32, 33, 34 can be formed on the first plastic backing 20a, and the spaces 30a, 30b among the three pads 32, 33, 34 can be connected with two connecting member 60a, 60b.
  • the three pads 32, 33, 34 can work as a sample pad 12, an auxiliary pad 13, and a conjugate pad 14, respectively.
  • Fig. 12 is a partially cut-away top view of a non-continuous immunoassay device according to the fifth embodiment of the present invention.
  • the immunoassay device of the fifth embodiment has substantially same configuration with that of the first embodiment except that the first and the second pads are separated by a predetermined distance, and the first and the second pads 32, 34 are also separated by a predetermined angle.
  • the two pads 32, 34 are positioned parallel to the ground, and the center point of the angle is the space 30 between the first and the second pads 32, 34, namely, the position of the connecting member 60.
  • the predetermined angle is 90 degree.
  • the capillary passage exists in the space 30 between the first pad 32 and the second pad 34, and is formed by the connecting member 60 extending from the upper case 52. Therefore, a mobile phase such as liquid sample migrates from the first pad 32 to the second pad 34 through the capillary passage.
  • the immunoassay device of the present invention has advantage that the configuration of the immunoassay device can be variously modified because pads 32, 34 are produced and positioned independently, and can be connected by a connecting member 60.
  • Fig. 13 is an exploded perspective view of a non-continuous immunoassay device according to the sixth embodiment of the present invention.
  • the immunoassay device of the sixth embodiment has substantially same configuration with that of the first embodiment except that a wick 38 is installed through the end sides of the upper and/or lower case 52, 72 for communicating the first pad 32 and out side of the device.
  • the first pad 32 works as a sample pad 12, and a liquid sample in the outside of the device is introduced into the first pad 32 through the wick 38. Therefore, the sample receiving hole needs not be formed on the upper case 52 in this embodiment.
  • the immunoassay by antigen- antibody reaction can be accomplished by immersing the wick 38 into a liquid sample.
  • the immunoassay device shown in Fig. 12 is capable of receiving a large amount of liquid sample, and needs not extra apparatus such as a syringe for applying a sample into the sample receiving hole.
  • the immunoassay device of the present invention is useful for various rapid tests.
  • Exemplary rapid test includes detections of pregnancy, ovulation, influenza virus, rotavirus, avian influenza, chlamydia and so on, in which the liquid sample is body fluids such as plasma, serum, urine, snivel, tear, and saliva, detection of malaria, AIDS, hepatitis C, hepatitis B, syphilis, helicobacter pylori, tumor markers(AFP, PSA, CEA), tuberculosis, SARS, Dengue fever, leprosy, and so on, in which the liquid sample is whole blood, detection of using drug such as opium, morphine, philopon, heroin, amphetamine, cocaine, and cannabis, and detection of biochemical terror by analyzing the existence of cholera, SEB(staphylococcal enterotoxin B), botulinum, ricin, anthrax, brucella, and salmonella.
  • body fluids such as plasma, serum, urine, snivel, tear, and saliva
  • the monoclonal antibodies against the nucleocapsid antigens of influenza virus type A and B were diluted with phosphate buffer solution, and the diluted antibodies were spread over a nitrocellulose pad (width: 25mm, pore size: 10 to 12D) to form test line 1 and 2, respectively.
  • An anti-mouse immunoglobulin G antibody was obtained by immunizing a goat with a mouse immunoglobulin G, and the antibody was diluted with phosphate buffer solution. The diluted antibody was spread over the nitrocellulose pad to form control line, and was dried in 37°C Thermostat for immobilization.
  • phosphate buffer solution containing 0.05 weight% of bovine serum albumin, 4 weight% of sucrose and 0.0625 weight% of ionic surfactant was sprayed on the blank space of the nitrocellulose pad, and the pad was dried in 30 0 C Thermostat for 60 to 120 minutes.
  • the nitrocellulose pad was attached to a polypropylene backing plate on which an adhesive is coated, then an absorbent pad(U.S.A., Millipore company) was also attached to the backing plate so that the absorbent pad and the nitrocellulose pad were overlapped by lmm.
  • the monoclonal antibodies against the nucleocapsid antigens of influenza virus type A and B were added to ImI of gold colloid- water solution to produce solutions of various antibody concentrations. Then, 15OmM sodium chloride solution, the amount of which was 1/10 of the volume of the gold colloid solution, was added to each gold colloid solution. The minimum amount of the gold colloid, which can stabilize the gold colloid solution, was determined from the above test.
  • the antibody against the nucleocapsid antigen of influenza type A and B and the gold colloid were mixed by the determined ratio, and the mixture was treated with 1 weight% bovine serum albumin.
  • the conjugate solution was centrifuged four times at 800rpm, and the upper serum was removed. Then, 1 weight% bovine serum albumin phosphate buffer solution was added again to the solution so that the absorbance of the conjugate solution was 10.
  • the obtained gold colloid-antibody conjugate solution was diluted with distilled water containing 0.5 weight% sucrose until its absorbance becomes 2, and the diluted solution was sprayed over a glass fiber pad with spray ratio of 101/25mm . Then, the glass fiber pad coated with the gold colloid-antibody conjugate solution was rapidly frozen with liquid nitrogen, and was freeze-dried in a freeze dryer for 20 hours. Fina Hy, the freeze-dried pad was cut into pieces of 0.7mm x 30mm size. The obtained antibody-gold conjugate pad and a sample pad were attached on a polypropylene backing plate on which an adhesive is coated so that the two pads were separated by lmm.
  • the nitrocellulose pad and the antigen-gold conjugate pad were manufactured by the same method of Experimental example 1.
  • the nitrocellulose pad was attached to a polypropylene backing plate on which an adhesive is coated, then an absorbent pad(U.S.A., Millipore company) was also attached to the backing plate so that the absorbent pad and the nitrocellulose pad were overlapped by lmm.
  • a sample pad for whole blood, an auxiliary pad and the antigen-gold conjugate pad were consecutively attached on a separate polypropylene backing plate on which an adhesive is coated so that the neighboring pads were separated by lmm, respectively.
  • the two produced strips were installed on a lower case with a separation distance of 2mm.
  • an upper case having three connecting members for connecting the sample pad, the auxiliary pad, the antigen-gold conjugate pad and the nitrocellulose pad was assembled with the lower case to produce the immunoassay device according to the fourth embodiment of the present invention (Fig. 8).
  • the positive and the negative syphilis samples were tested with the produced immunoassay device, and the test was carried out with good sensitivity.
  • the nitrocellulose pad and the antibody-gold conjugate pad were manufactured by the same method of Experimental example 1.
  • a sample pad, the antibody-gold conjugate pad, and the nitrocellulose pad were consecutively attached on a polypropylene backing plate on which an adhesive is coated so that the neighboring pads were separated by lmm, respectively.
  • an absorbent pad(U.S.A., Millipore company) was also attached to the backing plate so that the absorbent pad and the nitrocellulose pad were overlapped by lmm.
  • the produced strip was installed on a lower case.
  • the nitrocellulose pad and the antigen-gold conjugate pad were manufactured by the same method of Experimental example 1.
  • a sample pad for whole blood, the auxiliary pad, the antigen-gold conjugate pad, and the nitrocellulose pad were consecutively attached on a polypropylene backing plate on which an adhesive is coated so that the neighboring pads were separated by lmm, respectively.
  • an absorbent pad (U.S.A., Millipore company) was also attached to the backing plate so that the absorbent pad and the nitrocellulose pad were overlapped by lmm.
  • the produced strip was installed on a lower case.
  • an upper case having three connecting members for connecting the sample pad, the auxiliary pad, the antigen-gold conjugate pad and the nitrocellulose pad was assembled with the lower case to produce the immunoassay device according to the third embodiment of the present invention(Fig. 7).
  • the positive and the negative HIV virus type 1 and 2 samples were tested with the produced immunoassay device, and the test was carried out with good sensitivity.
  • the immunoassay device was produced according to the method of Experimental example 3.
  • the produced immunoassay device corresponds to the immunoassay device of the sixth embodiment of the present invention(Fig. 13).
  • the immunoassay device of the present invention is capable of controlling the migration speed of a mobile phase flowing through the pads for immunoassay, and thus controlling the antigen-antibody reaction time according to the kind of the antigen- antibody reaction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Clinical Laboratory Science (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)

Abstract

L'invention concerne, d'une part, un dispositif d'immunodosage non continu doté d'au moins deux tampons séparés destinés à une analyse d'immunodosage, capable de réguler la vitesse de migration d'une phase mobile entre les tampons séparés et, d'autre part, une méthode d'immunodosage utilisant ce dispositif. Le dispositif d'immunodosage présente un premier tampon qui renferme un tampon d'échantillon servant à recevoir un échantillon liquide, un second tampon qui est spatialement séparé du premier tampon d'une distance prédéterminée et vers lequel l'échantillon liquide migre, un boîtier supérieur servant à recouvrir les parties supérieures des premier et second tampons, un boîtier inférieur servant à recouvrir les parties inférieures des premier et second tampons, et un élément d'accouplement formé sur le boîtier supérieur ou le boîtier inférieur et situé entre les premier et second tampons afin de constituer un passage permettant le déplacement de l'échantillon liquide.
EP05726908A 2005-02-02 2005-03-03 Dispositif d'immunodosage non continu et méthode d'immunodosage doté dudit dispositif Withdrawn EP1844331A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020050009677A KR100506165B1 (ko) 2005-02-02 2005-02-02 비연속식 면역분석장치 및 이를 이용한 면역분석방법
PCT/KR2005/000591 WO2006083053A1 (fr) 2005-02-02 2005-03-03 Dispositif d'immunodosage non continu et methode d'immunodosage dote dudit dispositif

Publications (2)

Publication Number Publication Date
EP1844331A1 EP1844331A1 (fr) 2007-10-17
EP1844331A4 true EP1844331A4 (fr) 2008-10-01

Family

ID=36777407

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05726908A Withdrawn EP1844331A4 (fr) 2005-02-02 2005-03-03 Dispositif d'immunodosage non continu et méthode d'immunodosage doté dudit dispositif

Country Status (3)

Country Link
EP (1) EP1844331A4 (fr)
KR (1) KR100506165B1 (fr)
WO (1) WO2006083053A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153110A1 (en) * 2006-10-25 2008-06-26 Tim Scherkenback Combination Rapid Detection Cartridges For Biological and Environmental Agents, Methods of Production and Uses Thereof
ES2670745T3 (es) 2007-05-17 2018-05-31 Advance Dx, Inc. Tarjeta de recolección de separador de fluidos
WO2009034563A2 (fr) 2007-09-14 2009-03-19 Nanocomms Patents Limited Système d'analyse
KR100943769B1 (ko) * 2009-06-22 2010-02-23 주식회사 바이오랜드 반응속도 조절 진단키트
JP5847158B2 (ja) * 2010-04-07 2016-01-20 バイオセンシア パテンツ リミテッド アッセイのための流動制御デバイス
JP5738622B2 (ja) * 2011-02-15 2015-06-24 株式会社 ベセル イムノクロマトグラフィー法に用いる検査容器
KR101894100B1 (ko) * 2012-02-29 2018-08-31 고려대학교 산학협력단 바이오 센서
KR101280054B1 (ko) 2012-05-31 2013-06-28 에스디 바이오센서 주식회사 현장진단 면역크로마토그래피용 동결건조 접합체 구조물, 이를 이용하는 면역분석용 키트 및 상기 키트를 이용하는 분석방법
US10088397B2 (en) 2013-06-19 2018-10-02 Advance Dx, Inc. Fluid separator collection card assembly
US10610862B2 (en) 2016-04-04 2020-04-07 Advance Dx, Inc. Multiple path sample collection card
CN106680476B (zh) * 2017-01-22 2018-08-03 英科新创(厦门)科技有限公司 一种用于分泌物样本的免疫层析检测装置
KR102147368B1 (ko) * 2018-03-30 2020-08-24 (주)타스컴 면역 크로마토그래피 센서 카트리지
CN111965347A (zh) * 2019-05-19 2020-11-20 王哲 基于流体控制的侧向层析检测装置和试剂盒
KR102461334B1 (ko) * 2020-02-14 2022-10-28 광운대학교 산학협력단 유속 조절부를 구비하는 상부 케이스 및 이를 구비한 현장용 진단 키트

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041182A1 (fr) * 1995-06-07 1996-12-19 Smithkline Diagnostics, Inc. Dispositif d'essai immunochimique avec support de specimen arrachable par torsion
WO2001020325A1 (fr) * 1999-09-16 2001-03-22 Immunetics, Inc. Dosages immunologiques de membrane permettant de detecter plusieurs maladies transmises par des tiques
US20010026944A1 (en) * 1999-04-21 2001-10-04 Roy Chung Immunoassay system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE210294T1 (de) * 1995-09-08 2001-12-15 Fujirebio Kk Immunoassay vorrichtung und testverfahren zu seiner verwendung
US5744096A (en) * 1997-02-21 1998-04-28 Cholestech Corporation Automated immunoassay cassette
KR100455298B1 (ko) * 2001-06-15 2004-11-09 주)녹십자 투명한 플라스틱 지지체를 가진 면역크로마토그래피 분석 디바이스 및 그의 제조 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041182A1 (fr) * 1995-06-07 1996-12-19 Smithkline Diagnostics, Inc. Dispositif d'essai immunochimique avec support de specimen arrachable par torsion
US20010026944A1 (en) * 1999-04-21 2001-10-04 Roy Chung Immunoassay system
WO2001020325A1 (fr) * 1999-09-16 2001-03-22 Immunetics, Inc. Dosages immunologiques de membrane permettant de detecter plusieurs maladies transmises par des tiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2006083053A1 *

Also Published As

Publication number Publication date
EP1844331A1 (fr) 2007-10-17
WO2006083053A1 (fr) 2006-08-10
KR100506165B1 (ko) 2005-08-05

Similar Documents

Publication Publication Date Title
US7432111B2 (en) Non-continuous immunoassay device and immunoassay method using the same
WO2006083053A1 (fr) Dispositif d'immunodosage non continu et methode d'immunodosage dote dudit dispositif
JP6387072B2 (ja) 免疫分析用キット及びこれを利用する分析法法
JP5090733B2 (ja) 血液型決定、血清クロスチェック及び抗体検索試験を同時に行うための装置及び方法
KR101540608B1 (ko) 가변 대조선을 구비한 분석 스트립 및 이를 구비한 진단 키트
EP2376906B1 (fr) Procédé d'amplification de signal dans une analyse immunochromatographique et kit immunochromatographique utilisant le procédé
CN111164095B (zh) 用于改进分析物检测的测定方法
US6663833B1 (en) Integrated assay device and methods of production and use
US7632687B2 (en) Hybrid phase lateral flow assay
US20110256638A1 (en) Downward or vertical flow diagnostic device and assay
WO2006047831A1 (fr) Dispositif et procede de detection
JP2009513939A (ja) 血液型抗原を同時に決定するための装置及び方法
KR100455298B1 (ko) 투명한 플라스틱 지지체를 가진 면역크로마토그래피 분석 디바이스 및 그의 제조 방법
JP2009517632A (ja) 改善された標的リガンドの検出
KR20210021316A (ko) 측면 유동 분석기의 신호-증폭을 위한 시스템, 장치, 및 방법
EP1566640A1 (fr) Dispositif d' échantillonnage, méthode et leur utilisation
WO2007061098A1 (fr) Analyseur et procede d’analyse
KR20190085684A (ko) 표면 개질된 금 나노입자를 이용한 측방유동 분석-기반 바이오센서
KR102631862B1 (ko) 면역 크로마토그래피 검사의 감도 향상을 위한 방법
JP2005257468A (ja) バイオセンサ
KR20190114631A (ko) 면역 크로마토그래피 센서 카트리지
WO2021193680A1 (fr) Bandelette réactive et dispositif comprenant une bandelette réactive
CN116964452A (zh) 用于快速分析来自受试者的毛细血管血样以旨在检测所述毛细血管血样中至少一种分析物的存在的系统

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070727

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE DE ES FR GB IT

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): BE DE ES FR GB IT

A4 Supplementary search report drawn up and despatched

Effective date: 20080828

17Q First examination report despatched

Effective date: 20090720

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091001